

House Committee on Health Care
State of Vermont
115 State Street
Montpelier, VT 05633-5301

February 13, 2024

Chair Houghton and members of the House Committee on Health Care,

On behalf of more than 167,000 Vermont residents with doctor-diagnosed arthritis, thank you for the opportunity to submit testimony in **support of H 233**, which addresses cost-sharing requirements and copay accumulator adjustment programs.

Copay accumulator programs prevent any co-payment assistance that may be available for high-cost specialty drugs from counting towards a patient's deductible or maximum out-of-pocket expenses. Many pharmaceutical manufacturers offer co-pay cards that help cover a patient's portion of drug costs. Traditionally, pharmacy benefit managers have allowed these co-payment card payments to count toward the deductible required by a patient's health insurance plan. With an accumulator adjustment program, patients are still allowed to apply the co-payment card benefits to pay for their medications up to the full limit of the cards, but when that limit is met, the patient is required to pay their full deductible before cost-sharing protections kick in.

Currently, the state of Vermont does not have a law to ensure that health insurers count co-payment assistance towards a patient's cost-sharing requirements. Now more than ever, it will be important for the Vermont State Legislature to act given 50% of marketplace insurers in the state have an accumulator adjustment program.¹

Legislation is necessary on this issue as patients are often unaware they are enrolled in one of these programs until they go to the pharmacy counter and realize they must pay the full cost of their medication, which can lead them to abandon or delay filling their prescription. These programs can be called different names, are often marketed as a positive benefit, and are disclosed many pages into plan materials, leading to a lack of awareness about them to patients.

In a recent Arthritis Foundation survey, 37% of patients reported they had trouble affording their out-of-pocket costs. Of those, 54% say they have incurred debt or suffered financial hardship because of it. The Arthritis Foundation also surveyed in 2017 asking patients about accumulator programs and found that if patients are faced

¹ Institute, T. A. (February 2023). Discriminatory Copay Policies Undermine Coverage for People with Chronic Illness. National Policy Office. Washington, DC: The Aids Institute. Retrieved from <https://aidsinstitute.net/documents/TAI-Report-Copay-Accumulator-Adjustment-Programs2023.pdf>

with a large, unexpected charge for a prescription drug, the top three reactions would be: abandoning or delaying their prescription fill; lengthening the time between doses; and asking their provider to switch to another drug.

H 233 resolves this issue by simply ensuring that when calculating a patient's overall contribution to any out-of-pocket maximum or any cost-sharing requirement, a health plan must include any amounts paid by the patient or paid on behalf of the patient by another person or third party.

Currently, 19 states, DC and Puerto Rico have enacted laws that require insurers to count third party payments, including copay assistance, towards cost-sharing limits and we strongly urge Vermont to pass this critical legislation as well.

The Arthritis Foundation thanks the committee for their consideration of H 233 and urges all members to support this critical legislation.



Melissa Horn
Director of State Legislative Affairs
Arthritis Foundation
1615 L St. NW Suite 320
Washington, D.C. 20036
240.468.7464 | mhorn@arthritis.org

